Trials / Completed
CompletedNCT00169130
ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma
Prospective Study of ACVBP Followed by Autologous Stem Cell Transplantation in Case of BCL-2 Overexpression in Non Previously Treated Patients Aged 60 Years or Less With Low-Intermediate Risk Diffuse Large B-Cell Lymphoma
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 300 (planned)
- Sponsor
- Lymphoma Study Association · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the study is to evaluate the efficacy of ASCT as consolidation in case of bcl-2 overexpression in non previously treated patients aged 60 years or less with low-intermediate risk diffuse large B-cell lymphoma who responded to ACVBP regimen. Our goal is to obtain a 15% increase of event-free survival at 2 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | doxorubicin | |
| DRUG | cyclophosphamide | |
| PROCEDURE | Autologous stem cell transplantation |
Timeline
- Start date
- 1999-10-01
- First posted
- 2005-09-15
- Last updated
- 2007-07-13
Locations
5 sites across 2 countries: Belgium, France
Source: ClinicalTrials.gov record NCT00169130. Inclusion in this directory is not an endorsement.